Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808429 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Atacicept in IgA Nephropathy
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02808429 is a Phase 2 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 16 participants.
The verdict
NCT02808429, a Phase 2 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The study hypothesis was that treatment with Atacicept would reduce proteinuria compared to placebo.
Interventions
- DRUG Placebo
- DRUG Atacicept 75 mg
- DRUG Atacicept 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2020-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02808429
The ClinicalTrials.gov registry entry for NCT02808429 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02808429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02808429 about?
NCT02808429 is a clinical study titled "Efficacy and Safety of Atacicept in IgA Nephropathy". This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The study hypothesis was that treatment with Atacicept would reduce proteinuria compared to placebo.
What is the current status of trial NCT02808429?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-01-31. Estimated completion is 2020-02-07.
What interventions are being tested in trial NCT02808429?
The interventions under investigation include: Placebo (DRUG), Atacicept 75 mg (DRUG), Atacicept 25 mg (DRUG).
Who is sponsoring clinical trial NCT02808429?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.